SCHEMBL30786154

SCHEMBL30786154

C=Cc1cc(C=O)ccn1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.34
KDM4E B2RXH2 2/20 0.34
PTGS2 P35354 1/20 0.34
RAB9A P51151 1/20 0.34
HDAC8 Q9BY41 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
CYP2A6 P11509 2/20 0.33
FGFR1 P11362 1/20 0.33
LMNA P02545 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
CCR1 P32246 1/20 0.32
CCR5 P51681 1/20 0.32
CCR8 P51685 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL986987 0.85 ALDH1A1 (0.38) ALDH1A1KDM4EPTGS2RAB9ACYP2A6
SCHEMBL1655827 0.85 ALDH1A1 (0.39) ALDH1A1RAB9AHDAC8CYP3A4CYP2D6
SCHEMBL29503544 0.85 ALDH1A1 (0.39) ALDH1A1RAB9AHDAC8CYP3A4CYP2D6
SCHEMBL29163627 0.83 ALDH1A1 (0.35) ALDH1A1HDAC8CCR1CCR5CCR8
SCHEMBL27845898 0.80 HDAC8 (0.36) HDAC8CYP3A4CYP2D6PSEN1PSEN2
SCHEMBL3256435 0.76 PARP1 (0.38) HDAC8MAP3K14HDAC3HDAC4HDAC1
SCHEMBL18036717 0.75 KDM4E (0.48) ALDH1A1KDM4ERAB9AHDAC8LMNA
SCHEMBL9347247 0.73 KDM4E (0.56) ALDH1A1KDM4ERAB9AHDAC8CYP2A6
SCHEMBL730405 0.73 CCR1 (0.42) ALDH1A1KDM4EPTGS2RAB9ACYP2A6
SCHEMBL29387096 0.73 CCR1 (0.42) ALDH1A1KDM4EPTGS2RAB9ACYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF BEYANG THERAPEUTICS CO LTD (CN) 2026-02-19 US disclosed
EP-4556466-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF Beyang Therapeutics Co., Ltd. (CN) 2025-05-21 EP disclosed
CN-119604488-A Protein tyrosine kinase inhibitor and medical application thereof 苏州必扬医药科技有限公司 2025-03-11 CN disclosed
WO-2024032584-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF 苏州必扬医药科技有限公司 2024-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049071-A1 PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF KDR, FLT1, ERBB2 ALDH1A1 3745/4885KDM4E 3216/4885PTGS2 1296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.